---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-352208"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2026-08-14T20:07:25+00:00"
generated_at: "2026-08-14T20:14:11.850462+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LeonaBio Q2 2026 net loss $19.0M; cash $51.1M; ELAINE-3 enrollment on track

## Summary
- Net loss $19.0M ($0.80/sh) vs $7.0M ($1.78/sh) in Q2 2025; R&D spend up to $12.9M from $3.7M.
- Cash, equivalents and investments $51.1M at June 30, 2026, down from $88.3M at Dec 31, 2025; ops cash burn $37.9M in quarter.
- ELAINE-3 Phase 3 trial enrolled 495 patients; enrollment completion expected Q4 2026, topline data 2H 2027.
- Up to $146M potential from cash-exercisable warrants from Dec 2025 financing to support development.
- Board additions: Fred Callori, Natalie Holles, Peter Silverman effective May 5, 2026; John Fluke retired May 4.

## SEC filing metadata
- accession: 0001193125-26-352208
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2026-08-14T20:07:25+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/0001193125-26-352208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/lona-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-352208
- JSON: https://secwatch.observer/filing/0001193125-26-352208.json
- Plain text: https://secwatch.observer/filing/0001193125-26-352208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.